Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
TipRanks on MSN
Kelun-Biotech’s ADC-PD-1 combo wins breakthrough therapy status in first-line lung cancer
An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...
Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.
NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...
DUBLIN--(BUSINESS WIRE)--The "Spotlight on Antibody-Drug Conjugates" report has been added to ResearchAndMarkets.com's offering. The first antibody-drug conjugate (ADC), Mylotarg, reached the market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback